Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1+ T cells in the tumor microenvironment.

Immunotherapy is an approved treatment option for head and neck squamous cell carcinoma (HNSCC). However, the response rate to immune checkpoint blockade is only 13% for recurrent HNSCC, highlighting the urgent need to better understand tumor-immune interplay, with the ultimate goal of improving pat...

Full description

Bibliographic Details
Main Authors: Patricia Gonzalez-Callejo, Zihan Guo, Tahereh Ziglari, Natalie Marcia Claudio, Kayla Hoang Nguyen, Naoki Oshimori, Joaquim Seras-Franzoso, Ferdinando Pucci
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0279400